Compugen Ltd. CGEN
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2000 · data as of November 13, 2026
Compugen Ltd. (CGEN) is a healthcare company listed in the US with a market value of about $199M. In fiscal year 2025 it had revenue of $73M and net income of $35M, a net margin of 48.6%.
Its overall Stock Analiz score is 3.2 out of 5 (average). The strongest part is financial health (5/5); the weakest is shareholder returns (1/5).
Key numbers: a P/E of 5.6, a price to free cash flow of 6.3, 5-year revenue growth of 105% a year, a 5-year average ROIC of -15%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 32% above the current price.
About Compugen
Compugen is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2000. Revenue went from $12M in 2014 to $73M in 2025, growth of about 17.5% a year. It was profitable in 1 of the last 10 years in our data. It spends 31% of revenue on research and development.
Score: 3.2 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
Checks not passed
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- Pays a dividend
- Share count down over 3 years (buybacks)
- 20% to 100% of free cash flow returned to shareholders
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $73M | $28M | $33M | $8M | $6M | $2M | — | $18M | — | $712000 |
| Net income | $35M | -$14M | -$19M | -$34M | -$34M | -$30M | -$27M | -$23M | -$37M | -$32M |
| Free cash flow | $31M | $49M | -$36M | -$35M | -$23M | -$28M | -$28M | -$13M | -$31M | -$22M |
| EPS (diluted) | $0.37 | $-0.15 | $-0.20 | $-0.36 | $-0.36 | $-0.31 | $-0.29 | $-0.24 | $-0.39 | $-0.33 |
| Net margin | 48.6% | -51.1% | -56.0% | -449.2% | -570.0% | -1484.9% | — | -127.0% | — | -4425.0% |
| ROIC | 29.6% | -20.3% | -15.3% | -35.1% | -32.0% | -25.6% | -67.2% | -49.3% | -100.9% | -40.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is Compugen’s P/E ratio?
About 5.6, based on the last twelve months of diluted earnings per share.
Is Compugen stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 32% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Compugen pay a dividend?
Not currently.
Is Compugen a good stock to buy?
We do not give buy or sell advice. Compugen scores 3.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.